Carl Ola Landgren, Md, Phd

This study is testing whether two different drug combinations can delay or prevent the development of multiple myeloma in people who have high-risk early-stage disease. Researchers will enroll 50 adults with smoldering myeloma to receive either teclistamab plus daratumumab or tal…